Arch Coal Inc (NYSE:ACI) has been given a consensus rating of “Hold” by the eighteen brokerages that are presently covering the company, AnalystRatingsNetwork.com reports. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating on the company. Arch Coal Inc (NYSE:ACI) stock performance was -0.64% in last session and finished the day at $4.66. Traded volume was 11.69million shares in the last session and the average volume of the stock remained 8.84million shares. The beta of the stock remained 1.85. Arch Coal Inc (NYSE:ACI) insider ownership is 0.54%.

Shares of MannKind Corporation (NASDAQ:MNKD) were the recipient of some unusual options trading activity on Monday. Traders purchased 21,101 call options on the company, AnalystRatings.NET reports. This is an increase of approximately 105% compared to the average daily volume of 10,311 call options. MannKind Corporation (NASDAQ:MNKD) dropped -1.86 percent to $5.80 Tuesday on volume of 8.76million shares. The intra-day range of the stock was $5.75 to $6.01. MannKind Corporation (NASDAQ:MNKD) has a market capitalization of $2.19billion.

An old-line Cincinnati business cranked out some new-economy-type stock gains when AK Steel Holding Corporation (NYSE:AKS) shares surged last week. A brighter outlook about steel makers’ ability to raise prices and a strong earning report fueled AK Steel Holding Corporation (NYSE:AKS) to a 13 percent gain in a week. That lifted the stock to $6.97. AK Steel Holding Corporation (NYSE:AKS)’s stock on Mar 25, 2014 reported a increase of 1.74% to the closing price of $7.02. Its fifty two weeks range is $2.76 -$8.47. The total market capitalization recorded $959.52million. The overall volume in the last trading session was 8.02million shares. In its share capital, AKS has 135.90million outstanding shares.

San Diego’s Arena Pharmaceuticals Inc (NASDAQ:ARNA), in a race to dominate the market for anti-obesity drugs, is expected to unveil an advertising campaign next month directly targeting consumers. On Tuesday, shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) advanced 0.50% to close the day at $6.05. Company return on investment (ROI) is -13.90% and its monthly performance is recorded as -13.69%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) quarterly revenue growth is 8.62%.